Oral therapy for erectile dysfunction

Archivos Espanoles de Urologia

Volumn 63, Issue 8, 2010, Pages 703-714

  Eardley, Ian ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Apomorphine; Erectil dysfunction; Phosphodiesterase type 5; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

ARTICLE; ERECTILE DYSFUNCTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 78149355620     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, Munarriz R, Lee SW. J Sex Med, Pharmacotherapy for Erectile dysfunction, J Sex Med, 2010, 7: 524-540
2. Eardley I. Optimisation of PDE5 Inhibitor Therapy in Men with Erectile Dysfunction: Converting 'Non-Responders' into 'Responders'. Eur Urol, 2006; 50: 31-33.
3. Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338(20): 1397-1404.
4. Padma-Nathan H. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Prac 1998; 52(6): 1-5.
5. Dinsmore W, Hodges M, Hargreaves C, Osterloh I, Smith M, Rosen R. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched, healthy control subjects. Urology Apr 1999; 53(4): 800-805
6. Tan HM, Moh CLC, Mendoza JB, Gana T Jr, Albano GJ, de la Cruz R, Chye PLH, Sam CCW, ASSESS-1 Study Group. Asian sildenafil efficacy and safety study (ASSESS-1): A double-blind, placebo-controlled flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology 2000; 56:635-640.
7. Chen KK, Hsieh JT, Huang ST, Jiaan DBP, Lin JSN, Wang CJ, for the Assess 3 Study Group. ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. Int J Impot Res. 2001 Aug; 13(4): 221-229
8. Rendell M, Rajfer J, Wicker P, Smith M, Sildenafil Diabetes Study Group. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized control trial. JAMA, Feb 3, 1999; 281(5):421-426
9. Boulton AJM, Selam JL, Sweeney M, Ziegler D. Sildenafil for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001; 44:1296-1301.
10. Giuliano F, Hultling C, El Masry WS, Smith M, Osterloh I, Orr M, Maytom M, for the Sildenafil Study Group. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Annals of Neurology 1999; 46(1):15-21.
11. Becher E, A Tejada Noriega, R Gomez and R Decia, Sildenafil citrate in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res (2002) 14, Suppl 2, S33-S41
12. F Gomez, H Davila, A Costa, A Acuna, LA Wadskier and P Plua. Efficacy and safety of oral sildenafil citrate in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled stu2. dy. Int J Impot Res (2002) 14, Suppl 2, S42-S47
13. Levinson IP, Khalaf IM, Shaeer KZM, Smart DO. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men in Egypt and South Africa. IJIR, 2003, 15, supplement 1, S25-S29
14. DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004; 15; 93(2):147-153
15. Tignol J, Furlan PM, Gomez-Beneyto M, Opsomer R, Schreiber W, Sweeney M, Wohlhuter C. Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. Int Clin Psychopharmacol. 2004; 19(4):191-199
16. Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, Mancia G. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens. 2004; 17(12 Pt 1):1135-1142
17. Katz SD, Parker JD, Glasser DB, Bank AJ, Sherman N, Wang H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol. 2005 1; 95(1):36-42.
18. Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng LJ, Stecher VJ. Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2006; 67(2):240-246
19. Heiman JR, Talley DR, Bailen JL, Oskin TA, Rosenberg SJ, Pace CR, Creanga DL, Bavendam T. Sexual function and satisfaction in heterosexual couples when men are administered sildenafil citrate (Viagra) for erectile dysfunction: a multicentre, randomised, double-blind, placebo-controlled trial. BJOG. 2007; 114(4):437-447
20. McVary KT, Kaufman J, Young JM, Tseng LJ. Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension. Int J Clin Pract. 2007; 61(11):1843-1849
21. Zonana Farca E, Francolugo-Vélez V, Moy-Eransus C, Orozco Bravo A, Tseng LJ, Stecher VJ. Self-esteem, confidence and relationship satisfaction in men with erectile dysfunction: a randomized, parallel-group, double-blind, placebo-controlled study of sildenafil in Mexico. Int J Impot Res. 2008; 20(4):402-408
22. Jones LA, Klimberg IW, McMurray JG, Padula R, Tseng LJ, Stecher VJ. Effect of sildenafil citrate on the male sexual experience assessed with the Sexual Experience Questionnaire: a multicenter, double-blind, placebo-controlled trial with open-label extension. J Sex Med. 2008; 5(8):1955-1964
23. Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol. 2009; 181(1):252-258
24. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC; IC351. On Demand Dosing Study Group. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001 Feb; 13(1):2-9.
25. Chen KK, Jiann BP, Lin JS, Lee SS, Huang ST, Wang CJ, Hsieh JT, SU CK, Costigan TM, and Emmick JT. Efficacy and Safety of on -demand oral tadalafil in the treatment of men with erectile dysfunction: A randomized, double blind, parallel, placebo controlled clinical study. J Sex Med.2004; 1: 201-208
26. Montorsi F. Nathan HP. McCullough A. Brock GB. Broderick G. Ahuja S. Whitaker S. Hoover A. Novack D. Murphy A. Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 172(3):1036-1041, 2004 Sep.
27. Eardley I. Gentile V. Austoni E. Hackett G. Lembo D. Wang C. Beardsworth A. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU International. 94(6):871-877, 2004
28. Skoumal R, Chen J, Kula K, Breza J, Calomfiresca N, Basson B, Kopernicky, V. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004; 46:362-369.
29. Seftel AD, Wilson SK, Knapp PM, Shin J, Wang WC Ahuya S. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. J Urol 2004; 172(2): 652-657.
30. McMahon CG, Stuckey BGA, Lording GA, Wittert GA, Murpy A, Shin J, Sutherlant PD, Palmer NR, Lowy MP, Jesudason DR, Fredlund P. A6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomized, double-blind, parallel-group, placebo-controlled study in Australian men. Int J Clin Pract 2005; 59(2):143-149.
31. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker S, and Beasley CM. Efficacy and safety of oral tadalafil in the treatment of men with erectile dysfunction: A randomized, double-blind, parallel, placebo-controlled clinical trial. J Sex Med 2005; 2:685-698.
32. Guo YL, Zhu JC, Pan TM, Ding Q, Wang YX, Cheong NF, Lim E, Shen W, Chan M, Venugopalan M. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol 2006; 13:721-727
33. Incrocci L, Slagter C, Slob AK, Hop WC. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(2):439-444
34. McMahon CG, Carson CC, Fischer CJ, Wang WC, Florio VA, Bradley JD. Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: a randomized, double-blind, placebo-controlled study in men with erectile dysfunction. J Sex Med 2006; 3:504-511.
35. Saylan M, Khalaf I, Kadioglu A, Zaki Shoair K < Beheiry A, Wang WC, Kopernicky V, Esen A. Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. Int J Clin Prac 2006; 60(7):812-819
36. Yip WC. Chiang HS. Mendoza JB. Tan HM. Li MK. Wang WC. Kopernicky V. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study, Asian Journal of Andrology. 8(6):685-692, 2006
37. Porst H, Giuliano FA, Glina S, Ralph D, Casabe AR, Mboussa AE, Shen W, Whitaker JS. Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5 mg and 10 mg in the Treatment Erectile Dysfunction: Results of a Multicenter Randomized, Double-Blind, Placebo-Controlled Trial. Eur Urol 2006; 50: 351-359.
38. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP III, Zhao Y, Yu A. Tadalafil Dosed Once a Day in Men with Erectile Dysfunction: A Randomized, Double-Bind, Placebo-Controlled Study in the United states Int J Impot Res, 2007; 19:95-103
39. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock G, Spera G, Rose L, lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabetes Med 2008; 25:138-146
40. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H. The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol 2004; 45: 634-641
41. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004;94:1301-1309
42. Fisher WA, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005;2:699-708.
43. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005; 2: 856-864
44. Edwards D, Hackett G, Collins O, Curram J. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006; 3: 1028-1036
45. Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006; 66: 210-216
46. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3:883-891
47. Chen KK, Paick JS, Ishii N. The efficacy and safety of vardenafil in East Asian men with erectile dysfunction. J Sex Med 2007; 4: 753-761
48. Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006; 163: 79-87
49. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007; 100: 130-136
50. Martin-Morales A, Meijide F, Garcia N, Artes M, Munoz A. Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. J Sex Med 2007; 4: 440-447
51. Miner M, Gilderman L, Bailen J, Cook D, Dawson K, Stanislaus M et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008; 5: 1455-1467
52. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh JK, Kim SC. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008; 5: 946-953
53. Paick JS, Choi HK, Kim SC, Ahn TY, Kim JJ, Park JK, Park KS, Lee SW, Kim SW, Park K, Jung H, Park NC. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian J Androl 2008; 10: 791-798
54. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008; 5: 2672-2680
55. Glina S, Toscano I, Gomatzky C, de Goes PM, Junior AN, Claro JF, Pagani E. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009; 6: 553-557
56. Eardley I. Wright P. Macdonagh R. Hole J. Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU International. 93(9)(pp 1271-1275), 2004.
57. Perimenis P. Markou S. Gyftopoulos K. Giannitsas K. Athanasopoulos A. Liatsikos E. Barbalias G. Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia. 36(3)(pp 106-110), 2004.
58. Perimenis P. Gyftopoulos K. Giannitsas K. Markou S.A. Tsota I. Chrysanthopoulou A. Athanasopoulos A. Barbalias G. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. International Journal of Impotence Research. 16(1)(pp 2-7), 2004.
59. Pavone C. Curto F. Anello G. Serretta V. Almasio P.L. Pavone-Macaluso M. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. Journal of Urology. 172(6 I)(pp 2347-2349), 2004
60. Eardley I, Mirone V, Montorsi F et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. Br JUrol Int 2005; 96: 1323-1332
61. Rodriguez Tolra JR, Cuadrado Campaña JM, Fumadó Ciutat L, Franco Miranda E. Prospective, randomized, open-label, fixed dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3: 901-909
62. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I, for the Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3: 1037-1049
63. Porst H. Behre H.M. Jungwirth A. Burkart M. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction. An open, randomized cross-over study with flexible dosing. European Journal of Medical Research. 12(2)(pp 61-67), 2007.
64. Afif-Abdo J, Teloken C, Damião R, Koff W, Wroclawski E, Yamasaki R, Otávio Torres L, Sabaneeff J, Faria G, Carlos Pompeo A, Cortado P, Glina S. Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. BJU Int, 102: 829-834, 2008
65. Giammusso B. Colpi G.M. Cormio L. Ludovico G. Soli M. Ponchietti R. Montorsi F. Panzironi C. Guastella B. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urologia Internationalis. 81(4)(pp 409-415), 2008.
66. Dula E. Keating W. Siami PF. Edmonds A. O'neil J. Buttler S. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology. 56(1):130-135, 2000
67. Von Keitz AT. Stroberg P. Bukofzer S. Mallard N. Hibberd M. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU International. 89(4):409-415, 2002
68. Dula E. Bukofzer S. Perdok R. George M. Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. European Urology. 39(5): 558-3; discussion 564, 2001
69. Heaton JP. Dean J. Sleep DJ. Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. International Journal of Impotence Research. 14(1):61-64, 2002
70. Gontero P. D'Antonio R. Pretti G. Fontana F. Panella M. Kocjancic E. Allochis G. Frea B. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. International Journal of Impotence Research. 17(1):80-85, 2005
71. Heaton JP. Apomorphine: an update of clinical trial results. International Journal of Impotence Research. 12 Suppl 4: S67-73, 2000
72. Fagan TC. Buttler S. Marbury T. Taylor A. Edmonds A. SL APO Study Group. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. American Journal of Cardiology. 88(7):760-766, 2001
73. Adams M.A. Perdok R.J. Padley R.J. Sleep D.J. Safety and tolerability of apomorphine SL in men with cardiovascular disorders. European Urology, Supplement. 1(3)(pp 28-32), 2002.
74. Ralph D.J. Sleep D.J. Perdok R.J. Padley R.J. Adverse events and patient tolerability of apomorphine SL 2 and 3 mg: A cross-study analysis of phase II and III studies. European Urology, Supplement. 1(3)(pp 21-27), 2002.